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Abstract
Background: The relationship between hepatitis C virus infection and risk of stroke remains inconsistent. This study
evaluates the risk of stroke in association with chronic hepatitis C infection in a longitudinal population-based cohort.
Methods: We identified 4,094 adults newly diagnosed with hepatitis C infection in 2002–2004 from the Taiwan National
Health Insurance Research Database. Comparison group consisted of 16,376 adults without hepatitis C infection randomly
selected from the same dataset, frequency matched by age and sex. Events of stroke from 2002–2008 were ascertained from
medical claims (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM, codes 430–438).
Multivariate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for potential associated factors
including HCV infection, age, sex, low-income status, urbanization, cessation of cigarette smoking, alcohol-related illness,
obesity, history of chronic diseases and medication use.
Findings: During 96,752 person-years of follow-up, there were 1981 newly diagnosed stroke cases. The HRs of stroke
associated with medical conditions such as hypertension, diabetes and heart disease were 1.48 (95% CI 1.33 to 1.65), 1.23
(95% CI 1.11 to 1.36) and 1.17 (95% CI 1.06 to 1.30), respectively, after adjustment for covariates. The cumulative risk of
stroke for people with hepatitis C and without hepatitis C infections was 2.5% and 1.9%, respectively (p,0.0001). Compared
with people without hepatitis C infection, the adjusted HR of stroke was 1.27 (95% CI 1.14 to 1.41) for people with hepatitis
C infection.
Conclusion: Chronic hepatitis C infection increases stroke risk and should be considered an important and independent risk
factor.
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Introduction
Chronic hepatitis C virus (HCV) infection is prevalent worldwide,
with approximately 170 million persons suffering from this disease
[1,2]. The epidemiology, natural history of chronic infection, virology
and medical therapy for HCV infection has been well documented [2].
However, pandemic HCV infection remains a serious problem of
global concern because of other long-term consequences of the
infection. Patients with HCV infection may progress to cirrhosis and
subsequently develop complications such as ascites, variceal bleeding,
encephalopathy and hepatocellular carcinoma [1,2].
Stroke is the second leading cause of death worldwide and the
leading cause of acquired disability in adults in most regions [3–5].
An international multicentre population-based study has identified
cardiac diseases, hypertension, diabetes, smoking, alcohol intake,
unhealthy diet, abdominal obesity, lack of exercise, psychosocial
stress and depression as risk factors associated with 90% of stroke
risk [5]. Nevertheless, other risk factors associated with the
prevalence of stroke require further study.
Substantial experimental and epidemiologic evidence has docu-
mented the potential role of HCV infection in the development and
progress of carotid atherosclerosis [6–9]. Altered cerebral metabolism
in patients with chronic HCV infection has been proposed [10], yet
the association of stroke with HCV infection as a consequence of
carotid atherosclerosis remains unclear. Although chronic HCV
infection is considered an independent risk predictor of cerebrovas-
cular mortality, whether HCV infection increases the incidental event
of stroke is undetermined [11]. To clarify the potential impact of
HCV infection on stroke, we conducted a population-based cohort
study using reimbursement claims from Taiwan’s National Health
Insurance Research Database with a follow-up period of 4 to 7 years.
Methods
Study design and sample
Taiwan’s National Health Insurance has documented all
medical claims for insured beneficiaries since 1996. With
identification numbers scrambled to protect patient privacy,
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disease codes, health care rendered, medications prescribed,
admissions, discharges, medical institutions and physicians pro-
viding services. In this longitudinal cohort study with a randomly
selected population of one million insured subjects, we identified
patients aged 20 years and older who were newly diagnosed with
HCV infection in 2002–2004 as the HCV cohort. The non-HCV
cohort comprised people aged $20 years randomly selected from
individuals without HCV infection at a ratio of 1:4 (exposed vs.
non-exposed), with frequency matching by age and sex during the
same time period. Patients with previous history of stroke were
excluded when establishing both cohorts. Overall, 20,470 insured
adults were included for the prospective analysis. This follow-up
started in 2002 to include all incident stroke cases or until
censoring due to death, loss to follow-up or other causes by the end
of 2008 to explore whether the HCV cohort had increased risk of
developing stroke.
Criteria and definition
The International Code of Diseases, Ninth Edition, Clinical Modification
(ICD-9-CM) was used to identify parameters from individual
health reimbursement claims. The HCV cohort consisted of
patients with diagnosis of HCV infection (ICD-9-CM 070.41,
070.44, 070.51 and 070.54), and the non-HCV cohort was
controls with no diagnosis of HCV infection. Both groups were
treated as fixed cohorts. HCV cohort was defined as patients with
primary diagnosis according to positive serum results during
hospitalization or outpatient visits. New stroke cases (ICD-9-CM
of 430–438) were further defined from emergency and inpatient
medical records afterwards. Co-existing medical conditions such as
obesity (ICD-9-CM 278), hyperlipidemia (ICD-9-CM 272.9),
diabetes (ICD-9-CM 250), ischemic heart disease (ICD-9-CM
410–414) and hypertension (ICD-9-CM 401, 402, 403, 404 and
405) were considered as covariates in this study. We further
considered associated alcohol-related illnesses as alcoholic psycho-
ses (ICD-9-CM 291), alcohol dependence syndrome (ICD-9-CM
303), alcohol abuse (ICD-9-CM 305), alcoholic fatty liver (ICD-9-
CM 571.0), acute alcoholic hepatitis (ICD-9-CM 571.1), alcoholic
cirrhosis of liver (ICD-9-CM 571.2) and alcoholic liver damage
(ICD-9-CM 571.3). In addition, subjects with history of cessation
of cigarette smoking were also identified. Medication use of statins
and angiotensin-converting enzyme (ACE) inhibitor during the
follow-up period were also considered in this study [12,13]. The
National Health Insurance Research Database has been verified as
a valid resource for population-based research [14].
Statistical analysis
We compared the distribution of demographic factors and the
proportions of comorbidities between the HCV and non-HCV
cohorts. The crude incidence rates of stroke were calculated in the
follow-up period until the end of 2008. The duration of
observation for each beneficiary was calculated until stroke was
diagnosed or the beneficiary was censored for death, migration or
discontinuation of insurance coverage. Adjusted hazard ratios
(HRs) with 95% confidence intervals (CIs) for HCV infection and
other factors associated with stroke risk were calculated using Cox
proportional hazard analyses. Two-sided probability values less
than 0.05 were considered statistically significant. We considered
associated factors in the univariate regressions with a p,0.2 in the
multivariate Cox proportional hazard model to estimate the
hazard ratios (HRs) for stroke. All analyses were performed by
SAS software version 9.1 (SAS Institute Inc., Carey, NC, USA).
Ethical Approval
Insurance reimbursement claims used in this study were from
Taiwan’s National Health Insurance Research Database, which is
available for public access. This study was conducted in
accordance with the Helsinki Declaration. To protect personal
privacy, the electronic database was decoded with patient
identifications scrambled for further public access for research.
According to National Health Research Institute regulations,
informed consent is not required due to decoded and scrambled
patient identification. However, this study was evaluated and
approved by Taiwan’s National Health Research Institutes.
Results
The eligible study subjects were 4094 persons in the HCV
cohort and 16,376 persons in the non-HCV cohort (Table 1).
The HCV infection cohort had a higher proportion of individuals
with low incomes, living in less urbanized areas, and visiting the
smoking cessation clinic compared with individuals without HCV
infection. Patients with HCV infection were also more likely to
have hypertension (42.4% vs. 34.9%, p,0.0001), hyperlipidemia
(40.4% vs. 26.8%, p,0.0001), diabetes mellitus (25.6% vs. 13.9%,
p,0.0001), ischemic heart disease (21.7% vs. 15.0%, p,0.0001),
alcohol-related disease (10.3% vs. 1.5%, p,0.0001) and obesity
(1.8% vs.1.1%, p=0.0003). There were significant differences in
medication use, with use of stains (p=0.0102) and ACE inhibitor
(p,0.0001) higher in the HCV group than in the non-HCV
group.
Table 2 shows that the incidence of stroke was significantly
higher in the HCV cohort than in the non-HCV cohort (25.3 vs.
19.3 per 1000 person-years) with a unadjusted HR of 1.30 (95%
CI 1.17 to 1.44). Female gender, greater age, lower income, living
in less urbanized areas, hyperlipidemia, diabetes, heart disease and
hypertension were also associated with the risk of stroke before
adjustment. The unadjusted HRs of risk of stroke for users of
statins and ACE inhibitor were 1.32 (95% CI 1.17 to 1.49) and
2.02 (95% CI 1.85 to 2.21), respectively. Those who received
smoking prevention services seemed to benefit from a decreased
risk of stroke.
After adjustment, HCV infection demonstrated a HR of 1.38
(95% CI 1.24 to 1.53) for stroke, or of 1.27 (95% CI 1.14 to 1.41)
in the multivariate model (Table 3). Age (HR 1.68, 95% CI 1.62
to 1.74), low income (HR 1.47, 95% CI 1.14 to 1.90), history of
diabetes (HR 1.23, 95% CI 1.11 to 1.36), ischemic heart disease
(HR 1.17, 95% CI 1.06 to 1.30) and hypertension (HR 1.48, 95%
CI 1.06 to 1.30) were also significant and independent factors
associated with increased risk of stroke. After adjustment, the use
of statins (HR 0.79, 95% CI 0.69 to 0.90) and ACE inhibitor (HR
0.75, 95% CI 0.67 to 0.83) were associated with reduced risk of
stroke.
Discussion
In this population-based cohort study, we found that chronic
HCV infection was associated with significantly increased risk of
stroke after controlling for conventional stroke risk factors. This
further upgrades previous associated findings that chronic HCV
infection might be linked with carotid atherosclerosis [6–9,15,16]
and acute myocardial infarction [17]. To the best of our
knowledge, our study is the first to investigate the relationship
between HCV infection and stroke event in a population-based
longitudinal cohort.
Previous studies have reported positive relationships between
HCV infection and carotid intima-media thickness, plaque and
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prevalence of HCV infection, risk factors and study design [6–
9,18–21]. A cross-sectional study supported the possible link
between HCV infection and carotid atherosclerosis in subjects
without severe liver dysfunction [20]. A prospective population-
based study also suggested that chronic infection plays an
important role in human carotid atherogenesis [22]. Positive
correlations between HCV infection, carotid atherosclerosis and
cardiovascular diseases also have been investigated in specific
patient populations. Among patients with type 2 diabetes,
significant association between HCV infection and ultrasono-
graphic-evident carotid atherosclerosis was noted [7]. HCV
infection is also closely associated with increased aortic stiffness
and cardiovascular events in dialysis patients [22]. In addition,
HIV-infected individuals with HCV co-infection were found to
have increased risk of cardiovascular disease and acute myocardial
infarction [18,19]. Aslam’s research review concluded that HCV-
positive subjects had higher incidence of carotid atherosclerotic
plaques compared to HCV-negative individuals [8].
Chronic HCV infection per se could be considered a chronic
inflammatory process that might play a role in the pathogenesis of
carotid arterial remodelling [7]. Localization of RNA of HCV in
human carotid plaques provides strong evidence for an association
between HCV infection and atherosclerosis [6]. Forton et al.
hypothesized that HCV infection might be related to cerebral
dysfunction, particularly neuropsychological symptoms and cog-
nitive impairment [23]. Furthermore, chronic HCV infection has
potential effects on cerebral metabolism which could not be
explained by hepatic encephalopathy or a drug-induced insult
[10]. However, further large-scale prospective studies are needed
to investigate these findings and hypotheses.
Controversy persists about correlation between HCV infection
and carotid atherosclerosis or cardiovascular disease [15–17]. A
Table 1. Comparisons in demographic characteristics and
comorbidities between cohorts with and without hepatitis C
infection.
Infection with hepatitis C
No (N=16,376) Yes (N=4094) p-value
Sex n (%) n (%) 1.00
Female 8184 (50.0) 2046 (50.0)
Male 8192 (50.0) 2048 (50.0)
Age, years 1.00
20–29 1200 (7.3) 300 (7.3)
30–39 2068 (12.6) 517 (12.6)
40–49 3384 (20.7) 846 (20.7)
50–59 3916 (23.9) 979 (23.9)
60–69 3392 (20.7) 848 (20.7)
$70 2416 (14.8) 604 (14.8)
Low-income 289 (1.8) 98 (2.4) 0.0082
Urbanization ,0.0001
Low 4014 (24.5) 1329 (32.5)
Moderate 4055 (24.8) 1041 (25.4)
High 3980 (24.3) 951 (23.2)
Very high 4327 (26.4) 773 (18.9)
Smoking cessation
servive
315 (1.9) 133 (3.3) ,0.0001
History of disease
Hypertension 5718 (34.9) 1736 (42.4) ,0.0001
Hyperlipidemia 4396 (26.8) 1655 (40.4) ,0.0001
Diabetes 2274 (13.9) 1047 (25.6) ,0.0001
Congestive heart
disease
2451 (15.0) 888 (21.7) ,0.0001
Alcohol-related
disease
252 (1.5) 421 (10.3) ,0.0001
Obesity 184 (1.1) 75 (1.8) 0.0003
Statin use 2112 (12.9) 467 (11.4) 0.0102
ACE inhibitor use 4049 (24.7) 1290 (31.5) ,0.0001
ACE, angiotensin-converting enzyme.
doi:10.1371/journal.pone.0031527.t001
Table 2. Incidences of stroke and Cox model measured
hazard ratios of stroke associated with hepatitis C infection,
demographic factors and comorbidities.
Univariate
Person-
years Cases
Incidence
rate
a HR (95% CI)
Hepatitis C
No 77686 1499 19.3 1.00 (reference)
Yes 19066 482 25.3 1.30 (1.17–1.44)
Sex
Female 48830 1069 21.9 1.00 (reference)
Male 47922 912 19.0 0.87 (0.80–0.95)
Age, years
20–29 7413 11 1.5 1.00 (reference)
30–39 12806 44 3.4 2.31 (1.19–4.48)
40–49 20804 160 7.7 5.17 (2.81–9.53)
50–59 23637 414 17.5 11.8 (6.48–21.5)
60–69 19690 645 32.8 22.1 (12.2–40.1)
$70 12403 707 57.0 38.5 (21.2–69.9)
Low-income 1689 60 35.5 1.75 (1.36–2.27)
Urbanization
Low 24636 686 27.8 1.58 (1.40–1.79)
Moderate 24258 468 19.3 1.10 (0.96–1.25)
High 23530 400 17.0 0.97 (0.85–1.11)
Very high 24328 427 17.6 1.00 (reference)
Smoking cessation
servive
2256 23 10.2 0.49 (0.33–0.74)
Alcohol-related
illness
3042 69 22.7 1.10 (0.87–1.40)
Obesity 1276 24 18.8 0.92 (0.61–1.37)
History of
hyperlipidemia
29059 749 25.8 1.41 (1.29–1.55)
History of diabetes 15162 576 38.0 2.20 (2.00–2.42)
History of heart
disease
15029 641 42.7 2.60 (2.36–2.85)
History of
hypertension
34095 1270 37.2 3.28 (2.99–3.59)
Statin use 12644 328 25.9 1.32 (1.17–1.49)
ACE inhibitor use 25010 820 32.8 2.02 (1.85–2.21)
aPer 1000 person-years.
ACE, angiotensin-converting enzyme; CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0031527.t002
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serum-positivity to hepatitis B surface antigen or hepatitis C
antibody was not associated with atherosclerotic signs such as
myocardial infarction, stroke and carotid plaques [16]. However,
several important limitations were involved in that study, including
inadequate and temporal serologic markers of HCV infection and a
cross-sectional, not longitudinal, study design. No association
between HCV infection and acute myocardial infarction was found
in a case-control study in the US Army [17]. Similarly, Bilora et al.
proposed no evidence associating HCV infection and carotid
atherosclerosis [15]. Another longitudinal study also failed to
confirm the association between chronic active hepatitis B/C and
carotidplaques due to its poorly defined diagnosis of serostatus [22].
Different study populations, limited sample size with traditional risk
factors of atherosclerosis and cerebrovascular disease, various
controlled risk factors and prevalence of HCV infection all might
contribute to these previous studies’ inconsistent findings.
A recent community-based prospective cohort study concluded
that chronic HCV infection is an independent risk predictor of
cerebrovascular deaths, showing a severity-dependent cerebrovas-
cular mortality with increasing serum HCV RNA level [11].
However, that study was limited by non-validated data derived
from the diagnosis on death certificate addressed by administrative
instead of medical personnel [11]. The previous study also did not
consider the effects of cardiovascular medication use on risk of
stroke [12,13]. As a population cohort, our findings suggest a
positive association between chronic HCV infection and stroke
event which was identified from National Health Insurance
records after the adjustment for sociodemographic factors, history
of diseases and cardiovascular medication use. Our study is the
first to report the association of HCV infection and increased risk
of stroke [14].
Our study differs from previous research on HCV infection and
stroke in several aspects. Retrospective exclusion of individuals
with previous medical history of stroke helps us define fresh cases
and clarify the correlation between HCV infection and develop-
ment of stroke. In addition, considering the major cardiovascular
risk factors for the data analysis, we could examine the effects of
HCV infection independently on stroke with risk confounders.
Several studies have positively linked HCV infection with type 2
diabetes and metabolic syndrome, which are important risk factors
for stroke [23–26]. Even though type 2 diabetes and hypertension
may increase the risk of stroke, this study demonstrated an
independent risk of stroke after controlling for diabetes and
hypertension in multivariate analyses. These results further suggest
HCV infection plays an independent and unique role in incident
stroke.
Our study has several limitations. Sub-clinical HCV-infected
patients might be included among our non-HCV cohort. The
history of hypertension, diabetes, hyperlipidemia, ischemic heart
disease, alcohol-related diseases and obesity was based on medical
claims in this study and might be underestimated. Moreover, our
study has no data for patient lifestyle associated with stroke. This
study mainly focused on clinical end points as detailed by medical
reimbursement claims, rather than on underlying pathologic
lesions in vessels. In addition, this study could not provide a disease
severity-dependent relationship between HCV infection and
stroke. We postulate that there might be a dose-response (titer-
dependent) relationship between serum HCV RNA levels and risk
of stroke event [11].
In conclusion, we identified an independent association between
chronic HCV infection and risk of stroke after controlling for
traditional stroke risk factors with a population-based longitudinal
cohort. Our data suggest a need for regular screening for
cardiovascular risk factors and preclinical atherosclerosis among
patients with HCV infection for early prevention of atherosclerotic
disease and stroke.
Author Contributions
Conceived and designed the experiments: CCL TLC. Performed the
experiments: CCL TCS FCS WHC TLC. Analyzed the data: CCL TCS
FCS WHC TLC. Contributed reagents/materials/analysis tools: TCS
FCS TLC. Wrote the paper: CCL.
References
1. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345: 41–52.
2. Flamm SL (2003) Chronic hepatitis C virus infection. JAMA 289: 2413–2417.
3. Feigin VL (2007) Stroke in developing countries: can the epidemic be stopped
and outcomes improved? Lancet Neurol 6: 94–97.
4. Strong K, Mathers C, Bonita R (2007) Preventing stroke: saving lives around the
world. Lancet Neurol 6: 182–187.
5. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, et al. (2010) Risk factors for
ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTER-
STROKE study): a case-control study. Lancet 376: 112–123.
6. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, et al. (2010) Hepatitis C
virus RNA localization in human carotid plaques. J Clin Virol 47: 72–75.
7. Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, et al. (2002)
Association between hepatitis C virus seropositivity, carotid-artery plaque, and
intima-media thickening. Lancet 359: 133–135.
8. Aslam F, Alam M, Lakkis NM (2010) Hepatitis C and carotid atherosclerosis: a
retrospective analysis. Atherosclerosis 209: 340–343.
9. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T (2003) Hepatitis C virus and
atherosclerosis in patients with type 2 diabetes. JAMA 289: 1245–1246.
Table 3. Multivariable Cox model measured hazard ratios and
95% confidence intervals for stroke.
Multivariate-adjusted
HR (95% CI)
Hepatitis C yes vs. no 1.22 (1.13–1.40)
Male vs. female 1.00 (0.91–1.09)
Age 10-year increment 1.05 (1.05–1.06)
Low-income yes vs. no 1.52 (1.17–1.96)
Urbanization vs. very high (Not included, p.0.2)
Low
Moderate
High
Smoking cessation
services
yes vs. no 0.64 (0.42–0.97)
Alcohol-related
illness
yes vs. no (Not included,
p.0.2)
Obesity yes vs. no (Not included,
p.0.2)
History of
hyperlipidemia
yes vs. no 0.96 (0.87–1.07)
History of diabetes yes vs. no 1.37 (1.23–1.52)
History of heart
disease
yes vs. no 1.25 (1.13–1.39)
History of
hypertension
yes vs. no 1.77 (1.57–1.99)
Statin use yes vs. no 0.79 (0.69–0.90)
ACE inhibitor use yes vs. no 0.75 (0.67–0.83)
ACE, angiotensin-converting enzyme; CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0031527.t003
Hepatitis C Virus Infection and Stroke
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e3152710. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, et al. (2001) Evidence
for a cerebral effect of the hepatitis C virus. Lancet 358: 38–39.
11. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, et al. (2010) Hepatitis C virus
infection and increased risk of cerebrovascular disease. Stroke 41: 2894–2900.
12. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML (2011) Validation of the National
Health Insurance Research Database with ischemic stroke cases in Taiwan.
Pharmacoepidemiol Drug Saf 20: 236–242.
13. Bilora F, Campagnolo E, Rinaldi R, Rossato A, Arzenton M, et al. (2009)
Carotid and femoral atherosclerosis in chronic hepatitis C: a 5-year follow-up.
Angiology 59: 717–720.
14. Vo ¨lzke H, Schwahn C, Wolff B, Mentel R, Robinson DM, et al. (2004) Hepatitis
B and C virus infections and the risk of atherosclerosis in a general population.
Atherosclerosis 174: 99–103.
15. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA (2006) No association
between hepatitis C virus seropositivity and acute myocardial infarction. Clin
Infect Dis 43: e53–e56.
16. Freiberg MS, Cheng DM, Kraemer KL, Saitz R, Kuller LH, et al. (2007) The
association between hepatitis C infection and prevalent cardiovascular disease
among HIV-infected individuals. AIDS 21: 193–197.
17. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, et al. (2010)
Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-
infected patients. HIV Med 11: 462–468.
18. Ishizaka Y, Ishizaka N, Takahashi E, Unuma T, Tooda E, et al. (2003)
Association between hepatitis C virus core protein and carotid atherosclerosis.
Circ J 67: 26–30.
19. Oyake N, Shimada T, Murakami Y, Ishibashi Y, Satoh H, et al. (2008) Hepatitis
C virus infection as a risk factor for increased aortic stiffness and cardiovascular
events in dialysis patients. J Nephrol 21: 345–353.
20. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, et al. (2001) Chronic
infections and the risk of carotid atherosclerosis: prospective results from a large
population study. Circulation 103: 1064–1070.
21. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, et al. (2003)
Nonalcoholic fatty liver disease in patients with hepatitis C is associated with
features of the metabolic syndrome. Am J Gastroenterol 98: 2064–2071.
22. White DL, Ratziu V, El-Serag HB (2008) Hepatitis C infection and risk of
diabetes: a systematic review and meta-analysis. J Hepatol 49: 831–844.
23. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ (2008) Hepatitis C virus
infection: molecular pathways to metabolic syndrome. Hepatology 47:
2127–2133.
24. Rouabhia S, Malek R, Bounecer H, Dekaken A, Bendali Amor F, et al. (2010)
Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection.
World J Gastroenterol 16: 3427–3431.
25. Biffi A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, et al. (2011)
Statin treatment and functional outcome after ischemic stroke: case-control and
meta-analysis. Stroke 42: 1314–1319.
26. Shah NR, Ogedegbe G (2010) ACP Journal Club. Review: first-line low-dose
thiazides and ACE inhibitors reduce mortality and morbidity in adults with
hypertension. Ann Intern Med 152: JC1–4.
Hepatitis C Virus Infection and Stroke
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31527